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Glioma Big Potassium Channel Expression in Human Cancers
and Possible T Cell Epitopes for Their Immunotherapy
Lisheng Ge,*,†,1 Neil T. Hoa,*,†,1 Andrew N. Cornforth,‡ Daniela A. Bota,x
Anthony Mai,* Dong In Kim,* Shiun-Kwei Chiou,† Michelle J. Hickey,{ Carol A. Kruse,{
and Martin R. Jadus*,†,‖
Big potassium (BK) ion channels have several spliced variants. One spliced variant initially described within human glioma cells is
the glioma BK (gBK) channel. This isoform consists of 34 aa inserted into the intracellular region of the basic BK ion channel. PCR
primers specific for this inserted region confirmed that human glioma cell lines and freshly resected surgical tissues from glioblas-
tomamultiforme patients strongly expressed gBKmRNA. Normal human brain tissue very weakly expressed this transcript. An Ab
specific for this gBK isoform confirmed that human glioma cells displayed this protein in the cell membrane, mitochondria, Golgi,
and endoplasmic reticulum. Within the gBK region, two putative epitopes (gBK1 and gBK2) are predicted to bind to the HLA-
A*0201 molecule. HLA-A*0201–restricted human CTLs were generated in vitro using gBK peptide-pulsed dendritic cells. Both
gBK1 and gBK2 peptide-specific CTLs killed HLA-A2+/gBK+ gliomas, but they failed to kill non-HLA-A2–expressing but gBK+
target cells in cytolytic assays. T2 cells loaded with exogenous gBK peptides, but not with the influenza M1 control peptide, were
only killed by their respective CTLs. The gBK-specific CTLs also killed a variety of other HLA-A*0201+ cancer cells that possess
gBK, as well as HLA-A2+ HEK cells transfected with the gBK gene. Of clinical relevance, we found that T cells derived from
glioblastoma multiforme patients that were sensitized to the gBK peptide could also kill target cells expressing gBK. This study
shows that peptides derived from cancer-associated ion channels maybe useful targets for T cell-mediated immunotherapy. The
Journal of Immunology, 2012, 189: 2625–2634.
T
he prolonged elevation of internal Ca2+ levels or by dis-
rupting Na+/H+ intracellular ratios results in a type of cell
death called “paraptosis” (1–4). This programmed cell
death pathway leads to necrosis (5, 6) and is characterized by
swollen mitochondria and endoplasmic reticulum (ER). Human
U251 (7) and rat T9 gliomas (8) immediately swelled upon acti-
vation of the big potassium (BK) channels using a BK ionophore;
paraptosis ultimately occurred within 18–24 h. Functional mem-
brane BK channels were detected on the human and rat glioma
cells by using patch-clamping techniques. Additionally, BK chan-
nels were found on the ER and the mitochondria (7, 8), providing
a plausible rationale for why these organelles are specifically
targeted in paraptosis. These ion channels are also called Maxi-K,
hSlo, mSlo, KCNMA1, calcium-dependent, large conductance-,
or voltage-activated channels (9–17). The complex interaction be-
tween various ions and their respective ion channels at the inva-
dopodia of the malignant gliomas is speculated to explain some
of the invasive properties of gliomas (18–20). This infiltrative
nature of high-grade gliomas is thought to be responsible for the
lethality of this tumor, since surgery and local irradiation fail to
eliminate these invasive cancer cells.
Four large BKa-chains associate with four smaller BKb-chains
to form the functional ion pore. Several variant BKa channels are
produced via alternative splicing pathways (21–24). Liu et al. (25)
described a novel BKa channel, which they named the glioma BK
channel (gBK), because it was initially described and genetically
cloned from malignant human D54 glioma cells. This variant gBK
channel consists of 34 aa inserted into the intracellular region of
the BKa ion channel. This variant form was only seen when an
additional 29-aa insert called the hbr5 region was simultaneously
coexpressed within the BKa channel. We developed PCR primers
specific for this gBK/hbr5 region and confirmed that human
glioma cell lines and freshly resected glioblastoma multiforme
(GBM) surgical specimens expressed this alternatively spliced
mRNA. These gBK transcripts were very weakly detected within
the brains of autopsy patients who died of noncancer-related
causes. This gBK marker should therefore be considered tumor-
associated, instead of being classified as a novel tumor-specific
biomarker. An Ab designed specifically for this gBK region
confirmed that human gliomas contained this insert at the protein
level, whereas normal brain was gBK2. Within the gBK-specific
protein sequence two putative T cell epitopes, gBK1 and gBK2,
are predicted to bind to HLA-A*0201 molecules. HLA-A*0201+
dendritic cells (DCs) were loaded with these gBK1 or gBK2
peptides and subsequently generated CTL responses in vitro. Both
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gBK1 and gBK2 peptide-specific CTL populations killed the
HLA-A2+/gBK+ gliomas (LN18, U87, U251, and T98G) but failed
to kill HLA-A22 glioma cells, D54 (HLA-A1+/HLA-A3+/gBK+),
or LNZ308 (HLA-A24+/gBK+) glioma cells in [51Cr]-release cy-
tolytic assays. Exogenously loaded gBK peptides added onto T2
cells, but not influenza M1 control peptide-loaded T2 cells, were
also specifically killed by their respective CTLs. This provides
further evidence that the gBK-specific CTLs killed gBK+ target
cells by HLA-A2 restriction. gBK-specific CTLs also killed HLA-
A2+ human embryonic kidney (HEK) cells that were transfected
with a plasmid that contained the gBK gene. T cells derived
from GBM patients could be restimulated with autologous DCs
that were pulsed with the gBK2 peptides and induced cell lysis
of gBK-transfected HEK cells and U251 glioma cells. To our
knowledge, this is the first report to demonstrate successful
targeting of HLA-A2+ tumors by CTLs directed toward ion
channel peptides. We detected this variant BK channel within
a variety of other human cancers, indicating the universal na-
ture of this target molecule. The gBK-specific CTLs also killed
AGS gastric, A549 lung adenocarcinoma, and MCF-7 breast
cancer cell lines that were both HLA-A2+ and gBK+. Thus, this gBK
ion channel provides novel epitopes for T cell immune-directed
therapy for several types of cancers.
Materials and Methods
Cell lines and surgical specimens
The human gliomas U87, U251, D54, LN18, LN229, T98G, and LNZ308
were described in Schwartz et al. (26). The HLA typing provides evidence
of the genetic differences of these cells. All cells were grown in DMEM
media (Sigma-Aldrich, St. Louis, MO) supplemented with 5–10% FBS
(Gemini Bioproducts, Calabasas, CA) and 0.1% antibiotics in a humidified
atmosphere of 5% CO2 at 37˚C. The human T2 cells were supplied to us by
Dr. Hideho Okada (University of Pittsburgh, Pittsburgh, PA). These cells
were grown in RPMI 1640 medium with 5–10% FBS.
Other human cells, including AGS (gastric carcinoma), HepG2 (hepa-
tocellular carcinoma), A549 (lung adenocarcinoma), Caco-2 (colon cancer),
HuTu80 (duodenal adenocarcinoma), NCI-H69 (HTB-119; small cell lung
cancer), Panc-1 (pancreatic cancer), and 293T HEK cells were obtained
from the American Type Culture Collection (Manassas, VA). MCF-7 breast
cancer cells were obtained from Ali Pedgram (Long Beach, VA). All of
these cells were grown in DMEM with 10% FBS.
Normal human brain neurosphere cultures
Neural stem cells were derived from the brain subventricular zone of
premature neonates who died shortly after birth. The stem cells were
cultured cells on Matrigel-coated dishes with DMEM/F12 (1:1 v/v)
medium (Irvine Scientific, Irvine, CA) containing 10% BIT 9500
(BSA, insulin, transferrin; Stem Cell Technologies, Tukwila, WA), 292
mg/ml glutamine (Irvine Scientific), 40 ng/ml basic fibroblast growth
factor, 20 ng/ml epidermal growth factor, and 20 ng/ml platelet-derived
growth factor-AB, 100 U/ml penicillin (Irvine Scientific), 100 mg/ml strep-
tomycin (Irvine Scientific), 50 mg/ml gentamicin (Sigma-Aldrich), 10 mg/ml
ciprofloxacin (Bayer), and 2.5 mg/ml amphotericin (Life Technologies/
Invitrogen, Carlsbad, CA) as previously described (26). For continuous
expansion, half of this medium was replaced every other day, and the
cultures were passaged every 7 d or when confluent using nonenzymatic
cell dissociation solution (Sigma-Aldrich). These cells were supplied by
Dr. Philip H. Schwartz (Children’s Hospital of Orange County, Orange, CA).
Human GBM and normal brain tissue
After informed consent forms were signed, remnant surgical tissue from
GBM patients was provided for research purposes. The debulking surgery
was performed by the Neurosurgery Department at the Chao Compre-
hensive Cancer Center (University of California, Irvine Medical Center,
Orange, CA). Normal human brain tissue was collected from autopsies
taken from patients who died of noncancer-related causes. Autopsies were
only performed after the next of kin signed the release forms for performing
autopsies. The nonglioma autopsies were performed at the Veterans Affairs
Medical Center (Long Beach, CA).
Paraffin-embedded glioma samples were obtained from autopsies done
at the Veterans Affairs Medical Center and University of California,
Irvine. Dr. Ronald C. Kim supplied us with these specimens that were
recut and mounted on glass slides. The sections were then deparaffined
and treated using a target retrieval unmasking solution (Dako, Carpinteria,
CA). The sections were then stained as described above. The specimens
were viewed under epifluorescence using the Nikon microscope as de-
scribed above.
Measuring image fluorescence/Gray intensity using ImageJ
software
The fluorescence images were captured using a Nikon Eclipse E600
fluorescence microscope system with the RTKE SPOT camera and SPOT
software (Diagnostic Instruments). The levels of fluorescence expression
were measured with a set of measurements (area, integrated density, and
mean Gray value) from ImageJ software, and the expressed average pixel
intensity (104 pixels2) values were calculated using the formula: average
pixel intensity = average integrated density 2 area of selected image mean
fluorescence of background readings. In brief, 40 randomly selected areas
(100 3 100 pixels) per image (n = 4 images) were used to analyze the
fluorescence intensity expressed in various tissues samples.
RT-PCR analysis
Total RNAwas isolated from the cells or tissues using an RNeasy Plus Mini
kit (Qiagen, Valencia, CA). One microgram total RNA and random primers
were used for cDNA synthesis using the AffinityScript qPCR cDNA
synthesis kit (Agilent Technologies, Santa Clara, CA). The PCR was
performed using the following primers to identify the gBK/hbr5 region
within the gBK transcripts: forward, 59-CGTTGGGAAGAACATTGTTC-
39, reverse, 59-AACTGGCTCGGTCACAAG-39. After the thermal cycling
was complete, the PCR products were run on a 1.5% agarose gel and stained
with the ethidium bromide. The gel image was then captured under the UV
light using the Eagle Eye II imager (Stratagene, San Diego, CA). The predicted
size of the amplicons was 186 bp. The image was scanned for its densitometric
reading by using the Un-Scan-It program (Silk Scientific, Orem, UT).
The same gBK/hbr5 primers used above were also used for quantitative
real-time PCRs. Real-time PCR reactions were performed on an iCycler iQ
detection system using a Brilliant SYBR Green kit (Stratagene). We used
identical techniques as described previously (27).
Cloning of the human gBK gene
We genetically cloned the BK into the plasmid pcDNA3.1 (Invitrogen)
using the mRNA purified from U251 cells as the source of the cDNA. By
DNA sequencing (DeWalch Technologies, Houston, TX) of this cDNA, this
BK cDNAwas determined to be the hbr5 isoform of the BK channel. For the
sake of time, we used in vitro mutagenesis techniques to insert the gBK
region into the hbr5 cDNA.
The following oligonucleotides were synthesized by Integrated DNA
Technologies (San Diego, CA). The mutagenic oligonucleotide primer no. 1
sequence is 59-GAATAAAAAAATGTGGCTGCAAACGGCGTTGGGAA-
GAACATTGTTCTTTGTGGAGACTGGAAAGCAAGGGAAATGTGA-
GAAGATTAAACTACTGCAGGGGTCAGCAAACTTTCTCTGTCAA-
AGTCAAGGTTGCAGCTAGATCACGCTATTC-39. The mutagenic oligo-
nucleotide primer no. 2 sequence is 59-GAATAGCGTGATCTAGCTG-
CAACCTTGACTTTGACAGAGAAAGTTTGCTGACCCCTGCAGTAG-
TTTAATCTTCTCACATTTCCCTTGCTTTCCAGTCTCCACAAAGA-
ACAATGTTCTTCCCAACGCCGTTTGCAGCCACATTTTTTTATTC-39.
Sequences in boldface type are nucleotides corresponding to the gBK.
In vitro mutagenesis was performed using a QuikChange II XL Site-
Directed Mutagenesis Kit (Agilent Technologies). This plasmid was then
transformed in XL10-Gold ultracompetent cells provided in the mutagenesis
kit. The inserted gBK region was confirmed by sequencing (San Diego
State University, San Diego, CA). The plasmid was then named pcDNA/
gBK. The plasmids were isolated using the Qiagen Maxi Prep kits for
further use.
Transfection of gBK into non-gBK–expressing HEK cells
HEK cells were seeded into 100-mm2 plates the day before transfection
to achieve a 35–40% confluence in standard tissue culture medium.
Qiagen Attractene transfection reagent was used to transfect the pcDNA/
gBK plasmid into the HEK cells, according to the instructions provided
by the manufacturer. The purified plasmid and Attractene transfection
reagent were mixed together for 15 min and added to the cell cultures.
After 48 h, the transfected cells were harvested as target cells for gBK-
specific CTLs. Expression of the gBK was then confirmed within the
transfected HEK cells using the purified anti-gBK Ab with intracellular
flow cytometry.
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Glioma BK channel peptides and polyclonal Abs against the
gBK or BK ion channels
The gBK peptides were designed to have the best binding to HLA-A0201
via the University of Heidelburg (SYFPEITHI) database (http://www.syf-
peithi.de/). The peptides toward gBK (SLWRLESKG gBK704–712 [gBK1
peptide] and GQQTFSVKV gBK722–730 [gBK2 peptide]) were synthesized
by GenScript (Piscataway, NJ), whereas the influenza M1 peptide (M158–66,
GILGFVFTL) was synthesized by Think Peptides (a division of ProIm-
mune, Oxford, U.K.).
The goat polyclonal Ab directed toward gBK was made by GenScript.
The gBK region that was deemed to be the best to generate an Ab toward the
gBK insert was RLESKGNVRRLNYC. An Ab toward the extracellular
region of the BKa channel (ENSGDPWENFQNNQC) was made in rabbits
by GenScript. This latter Ab was designed to bind human, rat, and mouse
BK channels. The C-terminal amino acids on both the gBK and BK
peptides were added with a cysteine to facilitate a better conjugation with
keyhole limpet hemocyanin as the carrier protein/immunogen.
Cell surface flow cytometry
The cells were stained with the mouse mAb specific for HLA-A2 allele
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). One half
million cells were incubated with 5 ml of the Ab on ice for 1 h. The cells
were washed three times and then the secondary anti-mouse IgG Ab
(FITC-labeled; Vector Laboratories, Burlingame, CA) was added. These
cells were incubated on ice for an additional hour. The cells were again
washed three times and then immediately analyzed on a FACSCalibur flow
cytometer (Becton Dickinson, Mountain View, CA). Ten thousand cells
were then analyzed. We used the Kolmogorov–Smirnov test to show sig-
nificant differences in flow cytometry expressions (p , 0.05) between the
cells stained with the specific Ab with that of cells stained with the sec-
ondary Ab alone.
To quantitate the CD4/CD8 ratio of the gBK-specific CTLs, one million
cells were stained with the CD4-FITC and CD8-PE Abs on ice for 1 h. The
cells were washed three times and 10,000 cells were analyzed with
a FACSCalibur flow cytometer.
Intracellular flow cytometry
Exponentially growing glioma cells (1 3 107 cells) at 50–70% confluence
were fixed in FCM Fixation buffer (Santa Cruz Biotechnology) on ice for
30 min. The cells were washed twice in ice-cold PBS. The cells were
permeabilized with Santa Cruz Biotechnology permeabilization buffer for
15 min on ice. The cells were washed again with FCM Wash buffer twice.
The resuspended cells were then divided into 106-cell aliquots and then
incubated with the primary Ab (anti-BK channel or BK channel Ab) for
1 h. The cells were washed twice and the secondary Ab conjugated with
FITC (Vector Laboratories) was incubated on ice for another hour. After
washing the cells twice, 10,000 cells were analyzed with a FACSCalibur
flow cytometer. We used the Kolmogorov–Smirnov test to show significant
differences in flow cytometry expressions (p , 0.05) between the various
cell lines.
Confocal microscopy
Glioma cells were incubated on cover slips that were collagen coated. The
cells were fixed with 2% paraformaldehyde and permeabilized with ice-cold
methanol/acetone. Tissues containing the glioma were stained with a 1:50
dilution of the Ab. The tissue was washed and then incubated 1 h with a
1:200 dilution of the FITC-conjugated secondary Ab (Vector Laboratories).
Tissue samples were washed and mounted with ProLong Gold anti-fade
reagent (Molecular Probes, Eugene, OR). Samples were imaged and an-
alyzed using a Nikon two-laser (helium/neon and argon) PCM 2000
confocal system on the Eclipse E800 microscope. To view the glioma
organelles, the cells were stained with either MitoTracker or Golgi tracker
obtained from Molecular Probes/Invitrogen. To view the ER, we used a
monoclonal mouse Ab directed toward calreticulin, which binds to the ER
(MBL International, Woburn, MA). The two different fluorescent dyes in
the labeled sample (FITC and Texas Red/Deep Red) were simultaneously
visualized. As a result, it can be inferred that the red-emitting and green-
emitting dyes are colocalized when areas are present in the images shown in
yellow.
Induction and evaluation of CTLs against glioma Ag peptides
To generate DCs, elutriated monocytes were collected from healthy normal
donors who were HLA-A0201+. The adherent monocytes derived from
PBMCs were cultured in AIM-V medium (Invitrogen/Life Technologies)
supplemented with 1000 U/ml recombinant human (rh)GM-CSF and 500
U/ml rhIL-4 (Cell Sciences, Canton, MA) at 37˚C in a humidified CO2
(5%) incubator. Immature DCs were harvested on day 6, resuspended in
AIM-V medium at 1 3 106 cells/ml with peptide (10 mg/ml), and incu-
bated for 4 h at 37˚C and then stimulated overnight with 500 IU/ml rhIFN-g
and 1 mg/ml LPS for maturation. Magnetic bead-purified (Miltenyi Biotec,
Auburn, CA) CD8+ autologous T cells were cocultured with mature
peptide-pulsed DCs at a ratio of 10:1 in AIM-V medium supplemented
with 5% human AB serum with 10 U/ml each rhIL-2 (R&D Systems,
Minneapolis, MN) and rhIL-7 (Cell Sciences). On day 7, lymphocytes
were restimulated with peptide-loaded mature DCs in AIM-V medium
supplemented with 5% human AB serum, 10 U/ml rhIL-2, and 10 ng/ml
each rhIL-7 and rhIL-15 (R&D Systems). The CD8+ cultured cells were
analyzed for CTL activity 5 d after the second stimulation by a standard
6-h [51Cr]-release assay.
The T2 cells were loaded with the exogenous peptides (1 mM) (same
gBK peptides as described in gBK peptide section) in RPMI 1640 media
without any serum for 1 h at 37˚C as described previously (28–30). The
cells were washed twice and then labeled with the [51Cr] (MP Biomedicals,
Irvine, CA) for an additional hour. These cells were washed and then used
as target cells (5 3 103 cells/well) in 6-h [51Cr]-release assays.
Glioma patient-derived material
Excess vitally frozen PBMCs, collected by leukapheresis of HLA-
A*0201+ GBM patients for DC vaccine trials at the University of Cal-
ifornia, Los Angeles Medical Center, were used for these studies. GBM
patient CTLs (pCTL-1, pCTL-2) and CTLs derived from a normal HLA-
A2+ donor (nCTLs) were generated as described above with rIL-4 and
GM-CSF. The DCs isolated from the PBMCs were pulsed with 10 ug/ml
gBK2 peptide overnight. After DC maturation, the autologous PBMCs
were then added and expanded as described above, with the exception of
the CD8+ selection step with Miltenyi Biotec beads. The early passage
(P2) autologous glioma cells derived from the patient from which pCTL-
1 were generated (i.e., syngeneic) were available for testing. The UC-
GBM1 glioma cells displayed moderate to strong positivity for gBK by
intracellular flow cytometry. Cytotoxicity assays were performed with
effector pCTL-1, pCTL-2, and nCTLs. The target cells included HEK,
HEK/gBK, U251, and UC-GBM1 cells. The average percentage lysis
from quadruplicate wells at various E:T ratios was determined from 6-h
[51Cr]-release assays.
Results
Human glioma cells express the novel gBK channel mRNA
Liu et al. (25) genetically cloned a novel gBK channel from human
D54 glioma cells, which was overexpressed by human high-grade
(World Health Organization grades III and IV) gliomas by per-
forming Western blotting. This novel BK channel contained a 63-
aa insert that incorporated both an hbr5 sequence (29 aa) along
with the gBK region (34 aa). We synthesized PCR primers
designed to specifically detect most of the gBK/hbr5 region. RNA
was isolated from four different freshly resected surgical World
Health Organization grade IV GBMs (GBM-1, -2, -3, and -4) from
the Neuro-Surgery Department at the Chao Comprehensive Can-
cer Center (University of California, Irvine, Orange, CA). Addi-
tionally, the mRNA derived from five malignant human glioma
cell lines was also used (D54, LN18, LN229, U87 and U251). The
cDNAwas synthesized and standard PCR techniques were used to
amplify this inserted region. The gBK/hbr5 PCR amplicons from
all gliomas had the predicted 186 bp whether they originated from
the surgical specimens or cell lines (Fig. 1A, top panel). These
amplicons were sequenced and verified to contain the gBK insert.
The densitometric readings of these RT-PCR products are dis-
played in Fig. 1A (lower panel). So far, every human glioma cell
line tested (n = 10) has strongly expressed gBK/hbr5.
Cells obtained from brain tissue collected from an autopsy
patient who died of a noncancer-related cause was grown in
neurosphere cultures, and tested for gBK transcripts. Additionally,
HEK cells also showed minimal expression of gBK. The RT-PCR
from the amplicons derived from neurosphere cells barely showed
any of the expected gBK band (Fig. 1B), whereas two human GBM
surgical specimens did. We used quantitative real-time RT-PCR to
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confirm that the gBK transcripts were only weakly present and
represented only 3–5% of the amount of the mRNA made by the
resected human GBM tissue.
gBK protein is expressed by malignant glioma cells
Fig. 2A shows that human U251 cells were positively stained with
the Ab directed at the basic unmodified BK ion channel. Because
the gBK contains an additional inserted region, all Abs directed
toward BK recognize BK as well as the gBK isoforms with the
hbr5 insert. A polyclonal Ab that specifically recognizes only the
gBK insert was generated. Our anti-gBK Ab only recognizes the
unique gBK insert and will not react toward the basic, unmodified
BK ion channel. The U251 cells stained positively with our Ab
toward gBK (Fig. 2B).
Screening of six different human glioma cell lines (D54,
LN18, LNZ308, T98G, U87, and U251) using intracellular flow
cytometry shows the presence of gBK channels within all glioma
cells. Expression of gBK was somewhat variable and was de-
pendent on which cell line was used. Fig. 2C contains data
representing three different experiments with the BK-stained
cells and shows mean peak channel numbers of these gBK+
cells. U251 cells demonstrated the best expression of gBK with
a mean peak channel value of 300. The LNZ308 cell line pos-
sessed the least amount of gBK positivity with a mean peak
channel value of 125, but it is still a good positive signal. We also
simultaneously stained the glioma cells with the gBK channel Ab
(Fig. 2D). An identical staining pattern was also seen here: U251
had the brightest staining intensity, wheras LNZ308 cells had the
lowest intensity.
To prove the specificity of this goat polyclonal Ab, we per-
formed intracellular flow cytometric analysis with U251 and
HEK cells using the pre- and postimmunized antiserum. Fig. 3A
shows some low binding of the preimmunized antisera with the
U251 glioma cells, whereas the serum from the immunized goat
displayed a much stronger staining of the U251 cells. However,
when the purified Abs were used, the background staining of
the gBK was dramatically reduced. Minimal staining was seen
when the anti-gBK Abs using the gBK2 cell line were derived
from normal brain neurosphere cultures (Fig. 3B), although
these cells strongly expressed the unmodified BK channels
(Fig. 3C).
We genetically cloned the gBK/hbr5 gene from U251 cells and
transfected the HEK cells with our gBK construct. Fig. 3D shows
that upon transfection with the gBK plasmid for 48 h, gBK
staining was observed within the HEK cells using the immunized
anti-gBK Ab.
U251 cells were cultured as adherent cells overnight onto cover
slips. The cells were first stained with the BK channel Ab since its
epitope was on the extracellular region. The cells were fixed and
permeabilized and then stained with the gBK Ab. Supplemental
Fig. 1 shows the dual staining of the two different BK channels on
the U251 cells.
gBK channels can be seen within clinical GBM, but not within
normal human brain
We next tested whether clinical GBM specimens possessed gBK at
the protein level by using the gBK Ab. Two autopsy cases of GBM
patients were examined. Both cases showed strong gBK expression
within the glioma. Fig. 4 (middle row) shows one representative
GBM case. As a negative control, we used normal brain tissue
from an autopsy of someone who died of a noncancer-related
cause. BK channels were detected within the normal brain (Fig. 4,
top middle panel), but no staining was seen within the normal
brain when we used the gBK (Fig. 4, top right panel). Fluorescent
densitometric readings are presented in Fig. 4 (bottom panel),
which show that the normal brain largely expresses BK, whereas
GBM tissue shows predominantly the gBK form.
FIGURE 1. RT-PCRs show the presence of gBK/hbr5 inserted sequence
within clinical and human GBM cell lines. (A) RNAwas isolated from four
surgical specimens (GBM-1, -2, -3, and -4) and five human glioma cell
lines (D54, LN18, LN229, U87, and U251). After the cDNA was syn-
thesized, it was amplified for 40 cycles. The amplicons were loaded onto
a 1.5% agarose gel and then stained with ethidium bromide and imaged
(top panel). Bottom panel, Staining intensity was detected by using the UV
transilluminator and then quantitated for its densitometric readings. (B)
Top panel, PCR results of HEK cells, normal human neurosphere cells, and
two human GBM surgical samples; bottom panel, densitometric readings.
FIGURE 2. Glioma cells express both BK and gBK channels as detected
by intracellular flow cytometry. U251 cells were fixed, permeabilized, and
stained with either the Ab toward the standard BK channel (A) or gBK-
specific Ab (B). The shaded area represents the value of the isotypic
controls. (C and D) Ten thousand D54, LN18, LNZ308, T98G, U87, and
U251 glioma cells were analyzed by intracellular flow cytometry using
either the BK or gBK Abs. The mean peak channel number and SEMs of
these cell lines are presented on the y-axis. (C) BK profile. (D) gBK
channel profile.
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gBK channels are found at the same cellular locations as with
BK channels
We stained the fixed-and-permeabilized U251 glioma cells with the
anti-gBK channel Ab and viewed these cells using immunofluo-
rescent microscopy. BK channels are found on the cell membrane,
on the mitochondria, and on the ER (7, 8). Fig. 5 (left column)
shows gBK+ staining (green). The yellow expressed in Fig. 5
(right column) shows the colocalization of the respective gBK
expression with various red stains of the mitochondria, Golgi, and
ER. No differences in staining were seen when gBK (green) and
BK Abs (red) were simultaneously compared (Fig. 5A, right
panel). Staining is particularly heavy at the edges of the cells,
primarily at the lamellipodia, microvilli, and filopodia. A com-
plete overlap was seen throughout the cells. Fig. 5B shows the
colocalization of the gBK with the mitochondria. Fig. 5C shows
the gBK colocalization with the Golgi. Finally, Fig. 5D shows the
staining with the anti-calreticulin Ab that stains the ER, and the
gBK also colocalizes there as well.
gBK peptide-pulsed DCs stimulate gBK-specific human CTLs
in vitro
We analyzed the region within the gBK protein sequence using the
SYFPEITHI database to identify potential HLA-A0201–restricted
epitopes. Two potential epitopes were identified, SLWRLESKG
(gBK704–712; gBK peptide 1) and GQQTFSVKV (gBK722–730; gBK
peptide 2). Both peptides scored as 16, indicating a reasonable
binding affinity to HLA-A2. These two gBK peptides were
synthesized. Human HLA-A2+ peripheral blood monocytes were
stimulated with IL-4 and GM-CSF for 1 wk. The immature DCs
were pulsed with either the specific gBK1 or gBK2 peptides for
1 d. The immature DCs were induced to differentiate into mature
DCs. We used these DCs as APCs to stimulate gBK-specific CTLs
by adding naive peripheral blood HLA-A2+ T cells. Afterward, the
T cells were expanded by stimulating them with rhIL-2, rhIL-7
and rhIL-15. We generated five different preparations of gBK1-
and gBK2-specific CTLs. Most of the CTL preparations were
CD8+ cells, with CD4+ cells comprising only 5–20% of the total
population.
These human HLA-A2–restricted CTLs displayed good cyto-
toxicity toward the human HLA-A2+ glioma cells, U251 (Fig.
6A), and LN18, T98G, and U87 (Fig. 6B) that possessed gBK.
These gBK1-specific CTLs effectively killed these HLA-A2+/
gBK+ glioma cells at all E:T ratios within 6 h. These values were
significantly different (p , 0.05) from the results of these same
CTLs responding to those non-HLA-A2–expressing gliomas that
are gBK+, D54, but are HLA-A1+ and HLA-A3+ (Fig. 6A), or
LNZ308, which is HLA-A24+ (Fig. 6B). Identical data were also
observed with the gBK2-specific CTLs that were specifically ac-
tivated toward the GQQTFSVKV, gBK722–730 epitope. All HLA-
A2+ U251, LN18, U87, and T98G glioma cells were killed (Fig.
6C, 6D). Concurrently, the HLA-A22, but gBK+, glioma cells (D54
and LNZ308) were not lysed. These data illustrate that functional
CTLs are generated against two predicted epitopes derived from
the gBK and can kill the gBK+ gliomas. Thus, the gBK protein
is being properly digested by the glioma’s proteasome and can
be recognized by the CTLs in the context of their HLA-A2
molecules.
gBK peptide-loaded T2 cells are killed by their respective gBK-
specific CTLs
The human T2 (B cell 3 T cell) hybridoma cell line is capable of
being loaded with exogenous peptides that bind to the HLA-0201
molecule (29–31). The gBK-specific CTLs were tested against the
T2 cells that were loaded with either influenza M1 control peptide
FIGURE 3. Specificity of the goat anti-gBK antiserum and purified anti-
gBK Ab. Fixed-and-permeabilized U251 and normal human brain neuro-
sphere cells were stained with either the preimmunized or postimmunized
goat sera or with the purified goat anti-gBK Ab. Results in (A) show that
(preimmunized) serum has some elevated background staining, whereas
the immunized antiserum had enhanced staining. When the isotypic con-
trol and purified anti-gBK Abs were used, a lowered left shift was observed
in both groups, as compared with the samples stained using whole sera.
Results in (B) show the normal brain neurosphere cells to have minimal
expression of gBK staining using the purified Ab, but they are positive for
BK channels (C). Results in (D) show the expression of gBK by HEK cells
that were either unmodified or transfected with the pcDNA/gBK plasmid
for 48 h using the purified anti-gBK Ab.
FIGURE 4. Human GBM, but not normal brain, displays gBK. Top
panel, top row, Staining profile of normal human brain; bottom row,
staining profile of human GBM tissue; left column, negative control
staining in the presence of a nuclear Hoescht red stain; middle column,
staining with the BK channel Ab (green); right column, staining of the
brain tissue using the gBK Ab (green). Original magnification 340. Bot-
tom panel, Summary of the average and SDs of green fluorescent staining
of 40 different fields using the ImageJ intensity staining detection profile
(as described in Materials and Methods).
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or gBK1- or gBK2-specific peptides. Fig. 7 shows that gBK1-
specific CTLs only killed the T2 cells loaded with the gBK1
peptide (Fig. 7A). Conversely, gBK2-specific CTLs only killed the
T2 cells pulsed with the gBK2 peptide (Fig. 7B). No gBK-specific
CTLs killed the T2 cells bearing the influenza M1 peptide. This
work confirms the previous experiment that shows that functional
CTLs can be specifically generated against gBK Ags via an HLA-
A2 restriction.
gBK channels can be found on other human cancer cell lines
We tested a variety of other human cancer cell lines that were
available to us and examined their gBK expression pattern. Fig. 8
shows the profile of gBK as detected by intracellular flow
cytometry using the anti-gBK channel Ab. All of the tumor cells
(Caco-2 colon cancer, HuTu-80 duodenal cancer, HepG2 hepa-
tocellular carcinoma, and Panc-1 pancreatic cancers) showed good
gBK expression that was comparable to the glioma cell lines. Only
NCI-H69 small-cell lung cancer cells appeared to have low to
moderate expression of gBK, possibly because the isotypic
background staining was higher. This work demonstrates that gBK
is not just specific for gliomas and can be found on other tumor
types.
gBK-specific CTLs can also kill other nonglioma cancer cells
The results obtained from Fig. 9 (right column) indicated that AGS
gastric cancer cells, A549 adenocarcinoma lung cancer, and MCF-
7 breast cancer cells all possess gBK as detected by intracellular
flow cytometry. These three cell lines also tested positive for
cell surface HLA-A2, as detected by flow cytometry. We tested
whether the gBK-specific CTLs could also kill these cells, so
cytotoxicity assays were initiated. Fig. 9 (left panels) demonstrates
that both gBK1- and gBK2-specific CTLs killed these three cancer
cells. The AGS and A549 cells were killed the best, whereas the
MCF-7 cells were only weakly killed, even though MCF-7 cells
possessed a higher level of gBK expression. We attribute this to
the fact that the HLA-A2 expression of the MCF-7 cells was lower
than that expressed on the other two cancer cell lines and hence
limits the functional actions of the CTLs. Thus, the gBK Ag
should therefore be considered a tumor-associated Ag and could
be applicable for other types of immunotherapy toward those
gBK+ types of tumors.
gBK-specific CTLs can be generated from GBM-derived
immune cells
We next tested whether gBK-specific CTLs could be generated
from GBM patient PBMCs. Vitally frozen archival material from
two HLA-A0201+ GBM patients and one normal donor (nCTL)
was used. Their DCs were first pulsed with gBK2 peptide and then
used to stimulate their respective autologous T cells. These T cells
were then expanded and tested in [51Cr]-release assays. The data
in Fig. 10 (top and middle panels) show that CTL populations
derived from the GBM patients lysed the gBK+ U251 glioma cells
and low-passage UC-GBM1 glioma cells (also gBK+), which were
isolated from the same patient as UC-pCTL1. Identical results
were obtained when nCTLs were derived from a normal HLA-
0201+ donor (Fig. 10, bottom panel). All the gBK2-specific CTLs
killed HLA-0201+ HEK cells that were transfected with the gBK
gene, but they failed to kill the nontransfected HEK cells.
Cold target inhibition studies were performed using either un-
labeled HEK or U251 cells in the presence of [51Cr]-labeled U251
cells to show further specificity of gBK2-directed CTLs. A rep-
resentative study is shown in Supplemental Fig. 2. The pCTL-1
lysed the 51Cr-labeled U251 cells in the absence of unlabeled
U251 cells or in the presence of the HEK cells. Significant inhi-
bition was observed when unlabeled U251 cells were added to the
CTLs responding to the radiolabeled U251 cells.
Discussion
Ion channels (potassium, calcium, and chloride channels) are
speculated to play an important role in glioma biology (18–20). BK
channels are one member of this triumvirate and are overex-
pressed by malignant glioma cells (9–14). BKa channels have a
complex splicing pattern with multiple forms known to be
expressed (21–24). A novel BK isoform was genetically cloned by
Liu and coworkers (25) in 2002 and was called the gBK. This gBK
splicing variant is identified as BK isoform 7 (SwissProt accession
no. Q12791-7; http://web.expasy.org/docs/swiss-prot_guideline.
html). In the present study, we confirmed the previous work that
shows that gBK mRNA exists genetically in surgically resected
World Health Organization grade IV GBM and malignant glioma
FIGURE 5. gBK channels are found in the same cellular locations as the
BK channels. U251 glioma cells were attached to glass cover slips over-
night and fixed and stained with the anti-gBK channel Ab. Left column,
gBK (green) staining of different U251 cells. (A) Middle panel, staining
profile with a BK channel Ab (red); right panel, merged image. Yellow
indicates that the proteins are located very close (100 nm) to each other.
(B) Staining patterns when the cells were stained with the Mito-Tracker.
(C) Golgi staining profile (Golgi tracker). (D) Cells stained with calreti-
culin, which specifically stained the ER (red). Original magnification
3100.
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cell lines using specific PCR primers (Fig. 1). By using a specifi-
cally designed Ab toward gBK, we proved that this molecule is
displayed as a protein (Figs. 2–5). Earlier studies (25) only used
a BK channel Ab to deduce that gBK protein was present. That Ab
used really could not distinguish whether either an hbr5 or gBK/
hbr5 insert was actively expressed at the protein level within the
gliomas. We show that gBK channels are specifically found in the
same intracellular sites as nonmodified normal BK channels. gBK
channels are found on the cell membrane and the edges of the cells
(Fig. 5, Supplemental Fig. 1). The staining intensity with the gBK
Ab was particularly high at the leading edges (lamellipodia) of the
glioma. The gBK also colocalized with the mitochondria, Golgi,
and ER. Thus, gBK resides in the identical places as do the BK
channels. We found that normal human brain tissue only contains
∼3–5% the amount of gBK mRNA as that found within malignant
human glioma tissue. Thus, gBK expression probably reflects an
increased transcriptional rate within glial cancers. This Ag should
be considered a tumor-associated Ag, as opposed to being truly
a tumor-specific Ag.
Besides finding gBK on glioma cells, we also found gBK on
different types of other human cancer cells (Figs. 8, 9). These
cancers included breast, colon, pancreatic, stomach, duodenal,
lung, and liver cancer cell lines. Others have shown differential
effects of BK channel modulators on breast (32) and prostate
cancers (33), but whether this reflects on the activity of gBK
within these cancer cells is unknown. Thus, it could be appropriate
to rename gBK to cancer BK (cBK) to reflect the more universal
nature of this tumor-associated ion channel. At this time, we will
continue to use the term gBK to promote a consistent terminology
and minimize any confusion that could result as a new name to
the literature. Besides, BK channels already have numerous
other aliases, such as Maxi-K, hSlo, mSlo, KCNMA1, calcium-
dependent, or large conductance- or voltage-activated channels
(15–17).
Previous in vitro studies showed that disrupted BK channel
functional activity inhibits glioma cell proliferation (33, 34) and
migration (35, 36). Earlier, we showed that prolonged activation of
BK channels of T9 or U251 gliomas in vitro causes cell swelling
and eventually leads to paraptosis (7, 8). When paraptotic BK
channel-activated/killed T9 cells were used as the immunogen,
T9-specific tumor immunity toward the T9 glioma cells was
generated within naive rats (8). BK channel activators were cre-
ated and successfully prevented cardiac reperfusion injury in
animals (37, 38). Clinical studies using these BK modulators
failed to be effectively translated in humans (39). Severe side-
effects and toxicities limited this approach. To directly kill gli-
oma cells in situ by prolonged BK channel activation via para-
ptosis, one would have to continuously infuse large concentrations
of BK channel activators either systemically or locally in the tu-
mor mass with the risk of affecting the normal surrounding brain.
FIGURE 6. gBK-specific CTLs will kill HLA-0201+
gliomas that also express gBK. gBK1- and gBK2-
specific T cells were generated and tested against either
LN18, T98G, U87, or U251 glioma (HLA-A0201+/
gBK+) or D54 cells (HLA-A1+/A3+, gBK+) and
LNZ308 (HLA-A24+, gBK+) in a 6-h assay. (A and B)
Results of one representative study done three times
that shows the results of the gBK1-specific CTLs. (C
and D) Results generated with the gBK2-specific
CTLs. *p , 0.05 from the non-HLA-A22 control
values.
FIGURE 7. T2 cells loaded with exogenous gBK peptides are specifi-
cally killed by the gBK1- or gBK2-specific CTLs. gBK1- or gBK2-specific
CTLs were generated in vitro and then tested against T2 cells that were
separately loaded with three different exogenous peptides (1 mM) for 1 h at
37˚C. The cells were washed and then labeled with [51Cr] for another hour
at 37˚C. The cells were then washed three times and used as target cells.
(A) Data generated when gBK1-specific CTLs were used. (B) Data when
gBK2-specific CTLs were tested against the various T2 cells. Represen-
tative data from three different experiments are shown. *p , 0.05 from the
influenza M1 control peptide (FLU) cytotoxicity values.
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Hence, either possible method would most probably lead to un-
wanted side-effects. Direct ways to specifically kill glioma in
a clinical setting using the current BK channel activators are
probably not feasible.
We also report in this study that the gBK inserted sequence
contains protein sequences that can be processed into peptides that
bind to the MHC and provoke human immune responses. Using the
SYPEITHI database for searching epitopes that predicts binding
to various MHC class I molecules, we found that two peptides,
SLWRLESKG (gBK704–712; gBK1 peptide) and GQQTFSVKV
(gBK722–730; gBK2 peptide), have reasonable scores (16) for
binding to the HLA-A0201 molecules. We successfully generated
human HLA-A2–restricted CTLs by loading DCs with gBK1 or
gBK2 peptides and then stimulating the naive CD8+ cells. These
CTLs killed all HLA-A2+ human glioma cells that coexpressed
gBK. To our knowledge, this is the first study that immunologi-
cally targets peptides derived from ion channels. These same
CTLs failed to kill gBK+ D54 (HLA-A1+ and HLA-3+ cells) or
gBK+ LNZ308 CTLs that were HLA-A24+ (Fig. 6). The gBK1-
and gBK2-specific CTLs also specifically killed human T2 hy-
bridoma cells that were exogenously loaded with their respective
gBK peptides. These CTLs failed to kill T2 cells loaded with the
irrelevant influenza M1 peptide (Fig. 7). The gBK CTLs also
killed the HLA-A2+ AGS gastric cancer, A549 adenocarcinoma
lung cancer, and MCF-7 breast cancer cells, which are gBK+ (Fig. 9).
Transfection of gBK2 HEK cells with the gBK gene induced
the expression of gBK (Fig. 3C), and more importantly now
made the HEK cells susceptible to gBK2-specific CTLs (Fig.
10). Therefore, gBK represents a universal Ag that is expressed
in many types of cancer cells, underscoring its broad thera-
peutic potential.
Using the gBK-specific sequence with the SYPEITHI analysis
database, at least 17 other human MHC class I alleles have the
predicted ability to bind gBK peptides with a score $16. Both
gBK1or gBK2 peptides scored a 16 with HLA-A0201. The HLA-
A03 allele had the ability to bind six gBK-specific peptides. The
gBK region also is predicted to bind at least six different 15-mers
to HLA-DR regions that can stimulate various CD4+ T cells. Thus,
gBK peptides potentially can be used to treat many non–HLA-A2+
cancer patients as well. The gBK insert is always transcribed with
another unique insert called hbr5. SYPEITHI analysis using the
29-aa hbr5 insert revealed another 13 possible human MHC class I
and 5 MHC class II molecules theoretically capable of binding
hbr5-specific peptides. Thus, the gBK/hbr5 sequence offers addi-
tional epitopes by which human T cell immune responses can be
harnessed for immunotherapy against a variety of gBK+ tumor cell
types.
If ion channels such as BK or other ion channels play a role in
tumor cell invasiveness as they have been postulated (18–20), then
targeting these membrane proteins might slow tumor cell invasion
FIGURE 8. gBK can be found on a variety of other
types of human tumor cell lines. Caco-2 (colon can-
cer), HuTu80 (duodenal adenocarcinoma), HepG2
(hepatocellular carcinoma), NCI-H69 (small cell lung
cancer) and Panc-1 (pancreatic cancer) cells were
fixed, permeablized, and stained with the anti-gBK Ab.
Afterward, the cells were washed and stained with the
anti-goat FITC labeled Ab. Ten thousand stained cells
were then analyzed. The U251 cells were supplied as
a reference point for staining intensity.
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by interfering with a key mechanism by which the cells regulate
their size/volume. It has been postulated that glioma cell size/
volume allows these cells to squeeze through the brain paren-
chyma by shrinking its leading edge, perhaps at the filopodia re-
gion. Once the tips of the invadopodia shrink, they can penetrate
between normal brain cells. Then these tips could swell and ex-
pand by gBK activation and help pull the remaining glioma cell
through that narrow opening. BK channels have been described as
being mechanosensitive; that is, when the membrane is stretched
the BK channels become activated (40). Thus, this ionic regulation
strategy can help explain some aspects of the motility of glioma
cells. Even if only the high-expressing gBK glioma cells are killed
by an immunotherapeutic approach, then the tumor cell population
as a whole might be sufficiently reduced, thereby slowing down
the tumor invasion. Targeting other ion channels, besides gBK
channels, could include chloride channel-1 (CLIC1 or its other
alias, CLCA1) or aquaporins. Both chloride channel-1 and aqua-
porins are also overexpressed in glioma (41–43). BK channel
activation leads to cell swelling, whereas CLIC1 activation leads
to cell shrinkage (7, 8, 44). Both of these functions, swelling and
shrinking, are needed for cell volume regulation and motility. The
BKb-chain associates itself with the BKa-chain, but also heter-
odimerizes with this chloride ion channel and modulates CLIC1/
CLCA1 activity (45). Therefore, attacking both ion channel reg-
ulatory pathways simultaneously could prove to produce syner-
gistic effects and control the glioma cell infiltration within the
brain. Thus, this immunotherapy may manage to slow down the
glioma cell migration and invasion in the normal brain. Using the
DCs and T cells from two human GBM patients, we generated
CTLs that killed U251 cells as well as the allogeneic cells of low-
passage glial tumor targets (UC-GBM1) (Fig. 10). Thus, this gBK
Ag is expressed on freshly isolated and cultured GBM cells. We
demonstrate that gBK-directed CTLs can be generated for GBM
patients.
In summary, we find that gBK channels are genetically found
within human malignant gliomas, either from surgical resections or
from glioma cell lines. A gBK-specific Ab confirmed that the actual
gBK sequence is produced as protein within human glioma cell
lines and a number of other cancer cells. gBK-specific peptides
provided sufficient stimulation to produce HLA-A2–restricted
human CD8+ CTLs that killed gBK+ tumor cells. Thus, immu-
nological targeting of tumor-associated ion channels maybe a
novel way to target the infiltrative nature of malignant gliomas and
perhaps other types of cancer.
FIGURE 9. gBK-specific CTLs will also kill AGS gastric cancer, A549
lung cancer and MCF-7 breast cancer cells. gBK1 and gBK2 CTLs were
tested against these HLA-A2+/gBK+ cancer cells in a 6-h [51Cr]-release
assay. Right column, Intracellular flow cytometry results using the gBK Ab
and the cell-surface HLA-A2 flow cytometric profile showing the intensity
of this Ag on nonpermeabilized cancer cells. The shaded area represents
the value of the isotypic controls. Left column, Effects of gBK1- and
gBK2-specific CTLs in 6-h assays. The cytolytic activities against the AGS
(A) and MCF-7 (C) cells were performed on the same day, whereas the
assay with the A549 adenocarcinoma cells (B) was done 1 wk after being
stimulated with immobilized anti-CD3 and anti-CD28 beads.
FIGURE 10. Cytotoxicity experiments with gBK-specific CTL effec-
tors and gBK-expressing and nonexpressing target cells. pCTL-1 and
pCTL-2 were generated from GBM patients and nCTLs were stimulated
from a normal donor. All CTLs originated from HLA-A0201+ individ-
uals. The DCs isolated from the PBMCs were pulsed with the gBK2
peptide prior to in vitro DC maturation. Autologous T cells were then
stimulated and further expanded. The target cells included the U251
glioma cell line, early passage (P2) UC-GBM1 glioma cells (autologous
to the pCTL-1), and HLA-0201+ HEK cells that were either non-
transfected or transfected with the gBK plasmid 48 h prior to the assay.
The gBK profile of the HEK cells is shown in Fig. 3D. All test symbols
represent data that were done in quadruplicate cultures. Top panel,
Results using the pCTL-1; middle panel, data generated with the pCTL-
2; bottom panel, results using the nCTLs. *p , 0.05 from the non-
transfected HEK control values.
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